Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

Breast Cancer Research

Volumn 9, Issue 3, 2007, Pages

  Toyama, Tatsuya ^a   Zhang, Zhenhuan ^a,b   Nishio, Mariko ^a   Hamaguchi, Maho ^a   Kondo, Naoto ^a   Iwase, Hirotaka ^b   Iwata, Hiroji ^c   Takahashi, Satoru ^a,d   Yamashita, Hiroko ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; PROTEIN MDM2; PROTEIN P53; TAMOXIFEN; DNA; PROLINE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CODON; DISEASE FREE SURVIVAL; DNA EXTRACTION; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MONOTHERAPY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; BREAST TUMOR; FEMALE; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; NUCLEOTIDE SEQUENCE; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BREAST NEOPLASMS; CODON; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROLINE; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 34548575637     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1682     Document Type: Article

References (44)

1. Vogelstein B Lane D Levine AJ Surfing the p53 network Nature 2000, 408:307-310 10.1038/35042675 11099028
2. Levine AJ p53, the cellular gatekeeper for growth and division Cell 1997, 88:323-331 10.1016/S0092-8674(00)81871-1 9039259
3. Michael D Oren M The p53-Mdm2 module and the ubiquitin system Semin Cancer Biol 2003, 13:49-58 10.1016/S1044-579X(02)00099-8 12507556
4. Lundgren K Montes de Oca Luna R McNeill YB Emerick EP Spencer B Barfield CR Lozano G Rosenberg MP Finlay CA Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53 Genes Dev 1997, 11:714-725 10.1101/gad.11.6.714 9087426
5. Cordon-Cardo C Latres E Drobnjak M Oliva MR Pollack D Woodruff JM Marechal V Chen J Brennan MF Levine AJ Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas Cancer Res 1994, 54:794-799 8306343
6. Bueso-Ramos CE Manshouri T Haidar MA Yang Y McCown P Ordonez N Glassman A Sneige N Albitar M Abnormal expression of MDM-2 in breast carcinomas Breast Cancer Res Treat 1996, 37:179-188 10.1007/BF01806499 8750585
7. Baccouche S Daoud J Frikha M Mokdad-Gargouri R Gargouri A Jlidi R Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients Ann NY Acad Sci 2003, 1010:752-763 10.1196/annals.1299.136 15033823
8. Matlashewski GJ Tuck S Pim D Lamb P Schneider J Crawford LV Primary structure polymorphism at amino acid residue 72 of human p53 Mol Cell Biol 1987, 7:961-963 365159 3547088
9. Dumont P Leu JI Della Pietra AC 3rd George DL Murphy M The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat Genet 2003, 33:357-365 10.1038/ng1093 12567188
10. Thomas M Kalita A Labrecque S Pim D Banks L Matlashewski G Two polymorphic variants of wild-type p53 differ biochemically and biologically Mol Cell Biol 1999, 19:1092-1100 116039 9891044
11. Sullivan A Syed N Gasco M Bergamaschi D Trigiante G Attard M Hiller L Farrell PJ Smith P Lu X Crook T Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo Oncogene 2004, 23:3328-3337 10.1038/sj.onc.1207428 15077186
12. Pim D Banks L p53 polymorphic variants at codon 72 exert different effects on cell cycle progression Int J Cancer 2004, 108:196-199 10.1002/ ijc.11548 14639602
13. Tommiska J Eerola H Heinonen M Salonen L Kaare M Tallila J Ristimaki A von Smitten K Aittomaki K Heikkila P Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival Clin Cancer Res 2005, 11:5098-5103 10.1158/1078-0432.CCR-05-0173 16033823
14. Bonafe M Ceccarelli C Farabegoli F Santini D Taffurelli M Barbi C Marzi E Trapassi C Storci G Olivieri F Franceschi C Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients Clin Cancer Res 2003, 9:4860-4864 14581358
15. Wang YC Chen CY Chen SK Chang YY Lin P p53 codon 72 polymorphism in Taiwanese lung cancer patients: Association with lung cancer susceptibility and prognosis Clin Cancer Res 1999, 5:129-134 9918210
16. Starinsky S Figer A Ben-Asher E Geva R Flex D Fidder HH Zidan J Lancet D Friedman E Genotype phenotype correlations in Israeli colorectal cancer patients Int J Cancer 2005, 114:58-73 10.1002/ijc.20645 15523694
17. Xu Y Yao L Ouyang T Li J Wang T Fan Z Lin B Lu Y Xie Y p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clin Cancer Res 2005, 11:7328-7333 10.1158/1078-0432.CCR-05-0507 16243804
18. Wegman P Stal O Askmalm MS Nordenskjold B Rutqvist LE Wingren S p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients Pharmacogenet Genomics 2006, 16:347-351 16609366
19. Sjalander A Birgander R Hallmans G Cajander S Lenner P Athlin L Beckman G Beckman L p53 polymorphisms and haplotypes in breast cancer Carcinogenesis 1996, 17:1313-1316 10.1093/carcin/17.6.1313 8681448
20. Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium J Natl Cancer Inst 2006, 98:1382-1396 17018785
21. Bond GL Hu W Bond EE Robins H Lutzker SG Arva NC Bargonetti J Bartel F Taubert H Wuerl P A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 2004, 119:591-602 10.1016/j.cell.2004.11.022 15550242
22. Arva NC Gopen TR Talbott KE Campbell LE Chicas A White DE Bond GL Levine AJ Bargonetti J A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells J Biol Chem 2005, 280:26776-26787 10.1074/jbc.M505203200 15908423
23. Hong Y Miao X Zhang X Ding F Luo A Guo Y Tan W Liu Z Lin D The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma Cancer Res 2005, 65:9582-9587 10.1158/0008-5472.CAN-05-1460 16230424
24. Menin C Scaini MC De Salvo GL Biscuola M Quaggio M Esposito G Belluco C Montagna M Agata S D'Andrea E Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status J Natl Cancer Inst 2006, 98:285-288 16478747
25. Boersma BJ Howe TM Goodman JE Yfantis HG Lee DH Chanock SJ Ambs S Association of breast cancer outcome with status of p53 and MDM2 SNP309 J Natl Cancer Inst 2006, 98:911-919 16818855
26. Millikan RC Heard K Winkel S Hill EJ Massa B Mayes L Williams P Holston R Conway K Edmiston S de Cotret AR No association between the MDM2-309 T/ G promoter polymorphism and breast cancer in African-Americans or Whites Cancer Epidemiol Biomarkers Prev 2006, 15:175-177 10.1158/ 1055-9965.EPI-05-0692 16434608
27. Wilkening S Bermejo JL Burwinkel B Klaes R Bartram CR Meindl A Bugert P Schmutzler RK Wappenschmidt B Untch M The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer Cancer Res 2006, 66:646-648 10.1158/0008-5472.CAN-05-3168 16423991
28. Bond GL Hirshfield KM Kirchhoff T Alexe G Bond EE Robins H Bartel F Taubert H Wuerl P Hait W MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 2006, 66:5104-5110 10.1158/0008-5472.CAN-06-0180 16707433
29. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 1991 19 403 410 10.1111/j.1365-2559.1991.tb00229.x 1757079
30. Yamashita H Nishio M Toyama T Sugiura H Zhang Z Kobayashi S Iwase H Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer Breast Cancer Res 2004, 6:R24-30 314452 14680497 10.1186/bcr738
31. Johnson VJ Yucesoy B Luster MI Genotyping of single nucleotide polymorphisms in cytokine genes using real-time PCR allelic discrimination technology Cytokine 2004, 27:135-141 10.1016/ j.cyto.2004.05.002 15304242
32. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB van de Rijn M Jeffrey SS Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001, 98:10869-10874 58566 11553815 10.1073/ pnas.191367098
33. Sorlie T Tibshirani R Parker J Hastie T Marron JS Nobel A Deng S Johnsen H Pesich R Geisler S Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 2003, 100:8418-8423 166244 12829800 10.1073/pnas.0932692100
34. Chang HY Nuyten DS Sneddon JB Hastie T Tibshirani R Sorlie T Dai H He YD van't Veer LJ Bartelink H Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci USA 2005, 102:3738-3743 548329 15701700 10.1073/pnas.0409462102
35. Santos AM Sousa H Portela C Pereira D Pinto D Catarino R Rodrigues C Araujo AP Lopes C Medeiros R TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer Biochem Biophys Res Commun 2006, 340:256-262 16364249
36. Ohmiya N Taguchi A Mabuchi N Itoh A Hirooka Y Niwa Y Goto H MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis J Clin Oncol 2006, 24:4434-4440 10.1200/JCO.2005.04.1459 16983111
37. Lim BH Soong R Grieu F Robbins PD House AK Iacopetta BJ p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma Int J Cancer 1996, 69:200-204 10.1002/ (SICI)1097-0215(19960621)69:3<200::AID-IJC9>3.0.CO;2-3 8682588
38. Kubicka S Claas C Staab S Kuhnel F Zender L Trautwein C Wagner S Rudolph KL Manns M p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: Relation to histological subtypes, Helicobacter pylori infection, and prognosis Dig Dis Sci 2002, 47:114-121 10.1023/ A:1013275706401 11837710
39. Pharoah PD Day NE Caldas C Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis Br J Cancer 1999, 80:1968-1973 10.1038/sj.bjc.6690628 10471047
40. Olivier M Langerod A Carrieri P Bergh J Klaar S Eyfjord J Theillet C Rodriguez C Lidereau R Bieche I The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clin Cancer Res 2006, 12:1157-1167 10.1158/1078-0432.CCR-05-1029 16489069
41. Barbareschi M Prognostic value of the immunohistochemical expression of p53 in breast carcinomas Appl Immunohistochem 1996, 4:106-116
42. Norberg T Lennerstrand J Inganas M Bergh J Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors Int J Cancer 1998, 79:376-383 10.1002/ (SICI)1097-0215(19980821)79:4<376::AID-IJC12>3.0.CO;2-3 9699530
43. Sotamaa K Liyanarachchi S Mecklin JP Jarvinen H Aaltonen LA Peltomaki P de la Chapelle A p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome Clin Cancer Res 2005, 11:6840-6844 10.1158/1078-0432.CCR-05-1139 16203772
44. Yi SY Lee WJ A p53 genetic polymorphism of gastric cancer: Difference between early gastric cancer and advanced gastric cancer World J Gastroenterol 2006, 12:6536-6539 17072987